NEW YORK (GenomeWeb) – Dutch ag-bio company KeyGene announced today that it has licensed its proprietary sequence-based genotyping technology to LGC and Bayer's Crop Science division.
Under the terms of the separate agreements, KeyGene has given Bayer a non-exclusive license for the in-house use of the SBG technology for crop improvement, and has given LGC a non-exclusive license for the commercial offering and use of SBG technology across all species, including field and vegetable crops, for the global market, the company said in a statement.
Financial terms were not disclosed for either deal.
"KeyGene is delighted with licensing its global SBG patent portfolio to Bayer's Crop Science division, an innovation-driven enterprise with competencies in the field of agriculture," KeyGene CSO Michiel van Eijk said in a statement, adding that the agreement "supports our shared commitment to crop improvement and meeting the challenges of sustainable food supply."
In a separate statement, van Eijk also added, "SBG is fully aligned with the needs of translational agriculture and plant breeding programs. We are very pleased with licensing our SBG patent portfolio to LGC."
LGC and Bayer have joined several other entities — including Floragenex, IGA Technology Services, and the University of Edinburgh — in licensing SBG technology from KeyGene.